Podcast

Three-Time Cancer Survivor Bikes 100 Miles for a Cause

Author(s):

Jamie Cesanek

In this episode of the “CURE® Talks Cancer” podcast, Joey Renick opens up about his cancer journey and explains how he went on to bike 100 miles for The Leukemia and Lymphoma Society.

Joey Renick received his first cancer diagnosis at age 3. By the time he was 22, he was undergoing treatment for his third diagnosis of the same disease, acute lymphoblastic leukemia (ALL). After many rounds of chemotherapy and radiation and a bone marrow transplant, he is now in remission.

In this episode of the “CURE® Talks Cancer” podcast, Renick shares his cancer journey and discusses the 100-mile bike ride he completed last year for The Leukemia and Lymphoma Society.

“Five years ago, if you would have said ‘You're gonna do a 100-mile bike ride in a single day,’ I would have probably laughed at you," said Renick. "It was extremely emotional, and we ended we actually ended our ride at the hospital that I did all my treatment at.”

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Image of a man with brown hair.
Image of a woman with short brown hair and glasses.
Image of a woman with short brown hair and glasses.
Image of a man with brown hair and a suit and tie.
Image of a woman with brown bobbed hair with glasses.
Related Content
Illustration of blood cells.
November 20th 2024

The FDA Approves Labeling Update for Sandoz in the Treatment of B-Cell CLL

Ryan Scott
The FDA has approved updated drug labeling for Sandoz in the treatment of B-cell chronic lymphocytic leukemia.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
"FDA" text.
November 15th 2024

FDA Approves Revuforj for Relapsed/Refractory Acute Leukemia Subset

Darlene Dobkowski, MA
Revuforj was approved by the FDA for adults and children with relapsed/refractory acute leukemia with a KMT2A translocation.
cancer horizons podcast logo: a white microphone on a blue background
March 4th 2024

Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

Alex Biese Brielle Benyon
In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.
Image of an orange background with the words "FDA Approval, developing story."
November 8th 2024

FDA Approves CAR-T Cell Therapy for Relapsed or Refractory B-Cell ALL

Darlene Dobkowski, MA
The CAR-T cell therapy Aucatzyl was approved for relapsed or refractory B-cell precursor acute lymphoblastic leukemia based on findings from the FELIX trial.
"FDA" text.
November 1st 2024

Oncology Drugs Approved by the FDA in October 2024

Darlene Dobkowski, MA
During October, the FDA approved drugs to treat diseases including breast cancer, lung cancer, leukemia and gastric cancer.